Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — ChromaDex — Q4 2020 Earnings Presentation
25 slides from Niagen Bioscience's earnings presentation, Mar 10, 2021
Slide 1: ChromaDex Earnings Conference Call Fourth Quarter 2020
e€ ChromaDex. TRU NIAGEN ChromaDex Earnings Conference Call Fourth Quarter 2020 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Nasdaq: CDXC | March 10, 2021 dl
Slide 2: FDA Disclaimer
(> ChromaDex. TRU NIAGEN FDA Disclaim
Slide 3: Q4 2020 & Recent Highlights
Q4 2020 & Recent Highlights ¥ Total company net sales up 9% and Tru Niagen® up 4% sequentially. Total company net sales up 18% and Tru Niagen® up 21% YoY. v Net loss was ($6.1) million or ($0.10) per share, compared to a net loss of ($8.9) million or ($0.15) per share in Q4 2019. ¥ Underlying busine
Slide 4: Management Team
Management Team Kevin Farr Chiet Fieanciol Oticer Rob Fried Chief Executive Officer Frank Jaksch Executive Chairman Former CFO, Mattol PriceWatormouse censed CPA E-Commerce & contertainmant industry executive Co-founded ChromaDex in 2000 Savoy Pictures, Columbia Pictures, Fried Films, Feeln, WHN, He
Slide 5: Scientific Update
Scientific Update
Slide 6: Scientific Advisory Board
Scientific Advisory Board ‘Charles Brenner, Ph.D. Roger Kornberg, Ph.D. Rudolph Tanzi, Ph.D. ‘Arod E Mann Famiy Chairman Kennedy Professor of Foundation Choir Professor of Structural ‘Neurology Department of Diabetes & Biology Harvard University Cancer Metabolism Stanford University City of Hops Lea
Slide 7: Most prominent human clinical research areas for Niagen
Most prominent human clinical research areas for Niagen® are vitality, locomotion, cognition, and sensory VITALITY COGNITION (incl, Cardiovascular, SENSORY Metabolic) (Neurological) Human Studies 58% 23% 12% 1% Conditions Studied ‘Type Il Diabetes (Insulin Parkinson's Disease Mild Concussion Neuropa
Slide 8: NR Research Impact is Accelerating
NR Research Impact* is Accelerating 1600 1400 1200 S g aVitality ® g ® Cognition = 800 = Sensory £ = Psychological = 600 = Pharmacokinetic/Safety & Basic Research ll a 400 200 0 “NR Research Impact by domains of intrinsic Capacity. 2013 2014 2015 2016 2017 2018 2019 2020 Chart data indexed to 2004,
Slide 9: Science Continues to Expand
Science Continues to Expand otinamide riboside initiated since prior update: + Two new human studies on + University of California, Davis (November 2020) + The objective is to investigate the impact of NR supplementation on mothers’ milk production in a Neonatal Intensive Care Unit (‘NICU’). + This
Slide 10: Financial Highlights
Financial Highlights
Slide 11: Q4 2020 Net Sales Mix
Q4 2020 Net Sales Mix Q4 2019 Q4 2020 e-Commerce, e-Commerce Watson's & Other 61% B28 19% Otheringredionts = $13.1 MM $15.4MM 1% Analytical Referen: Standards & Servic 0) Niagen® Ingredient ‘ Analytical Reference Niagen® Ingres Other B2B. sianderds & Services (1) 15% % 19% Other ingredients 5% 1% >»
Slide 12: Q4 2020 Net Sales
Q4 2020 Net Sales Q4 2020 Net Sales Growth Rates ($ in millions) YoY % Q0Q % (vs Q4 2019) (vs Q3 2020) wacors sone ozo I 29 Niagen® Ingredient LJ 22 414% +154% Analytical Reference Standards & Services (1) $12.3 08 Other Ingredients | 04 +8% 80% Total 418% +9% Continued strong growth offset by lower
Slide 13: Full Year 2020 Net Sales
Full Year 2020 Net Sales FY 2020 Net Sales ($ in millions) YoY % (vs FY 2019) e-Commerce Watson's & Other B2B Niagen® ingredient — 77 +45% Analytical Reference 40 Standards & Services (1) : Other Ingredients in 24 +61% Total +28% Continued strong growth in Tru Niage! gen® and other ly offset by lowe
Slide 14: 2018 — 2020 YTD Net Sales Summary
2018 — 2020 YTD Net Sales Summary Other B28 Total TRU NIAGEN 3037 52 65185 75 ar 97 102 4 17149 = ara| NIAGEN Ingredient 4319 40 405.2 44 44 o7 20 20 20 og 274 ‘NAGEN Related Revenues cr a a ae OD 70s at Tat 137284 8a Other Ingredients 1109 09 0534 04 03 05 ot Total Net Sales INIAGEN Related Revenue
Slide 15: Q4 2020 vs Q3 2020 Key P&L Metrics
Q4 2020 vs Q3 2020 Key P&L Metrics | aszoz0 | 32020 [Notes (in thousands) Net Sales Gross Profit % of Net Sales Selling and Marketing % of Net Sales Research and Development General and Administrative Other Total Operating Expense Operating Loss (> ChromaDex. Tru Niagen® business up 4% driven by glo
Slide 16: Q4 2020 vs Q4 2019 Key P&L Metrics
Q4 2020 vs Q4 2019 Key P&L Metrics ‘Tru Niagen® business up 21% with growth in global e-commerce, Net Sales $15,445 $13,089 Watsons, international launches (Australia, U.K.) and new platforms Gross Profit % of Net Sales 61.0% 87.0% product cost savings and overall scale on supply chain overhead Sell
Slide 17: Adjusted EBITDA Summary
Adjusted EBITDA Summary Reconciliation of Non-GAAP Financial Measures (In thousands) Three months ended War. 31, Jun.30, Sep. 30, Dec. 31, Mar. 31, Jun.30, Sep.90, Dec. 31, Mar.31, _Jun.30, Sep. 30, Dec. 31, 2018-2018 2018018 20192019 201920192020 202020202020 Net loss, as reported $ (8,443) $ (8,05
Slide 18: Q4 2020 Operating Loss vs Q4 2019
Q4 2020 Operating Loss vs Q4 2019 (3.0) (4.0) 0.2 On ao je tdig — (0.1) <= (5.0) (0-4) (0.2) al (6.0) (1.2) (6.1) (7.0) 13 7 ia (9.0) (8.9) (10.0) Volume Elysium Bad Debt RD Other Gra Sales & Marketing (Q4 FY19 Actual Gross Margin. Equity Comp Severance and Legal Q4FY20 Operating Loss Improvement (G
Slide 19: Quarterly Balance Sheet Highlights
Quarterly Balance Sheet Highlights (in thousands) 12/31/18 | 3/31/19 | 6/30/19 | 9/30/19 | 12/31/19 | 3/31/20 | 6/30/20 | 9/30/20 | 12/31/20 | Key Drivers Cash used in operations Cash $22,616 $19,327 $19,760 $18,879 $18,812 $13,608 $18,890 $15,478 | $16,697 _to grow the business pl lus Investments t
Slide 20: Quarterly Cash Flow Highlights
Quarterly Cash Flow Highlights (in thousands) FY 2018 | 3/31/19 | 6/30/19 3/31/20 | 6/30/20 | 9/30/20 | 12/31/20 Net Loss $(33,316) $ (8,337) $ (7,755) $ (7,202) $ (8,853)*) | $(32,147) $(5,902) $(3,711) $(4,215) $(6,097) | $ (19,925) Working Capital 5,059 | 2,888" (3,969) (3,063) 6,170 [ 2,026 (1,5
Slide 21: 2020 Full Year Outlook Recap
2020 Full Year Outlook Recap (in thousands) 2019 Actual 2020 Outlook 2020 Actual Comments Achieved? , Total net sales grew by +28% Net Sales $46,291 Continued growth In safes of $59,257 and Tru Niagen® net sales v Tru Niagen® grew by +31% year-over-year Gross Margin % 55.7% Continued improvement 59.
Slide 22: 2021 Financial Outlook
2021 Financial Outlook (in thousands) 2019 Actual 2020 Actual PUAMIRComenirs i + Global e-Commerce business Net Sales $46,291 $59,257 Continued, steady revenue growth | Existing + new strategic partnerships Gross Margin % 55.7% 59.5% Slightly better than 60% + Continued cost savings initiatives (as
Slide 23: Adjusted EBITDA 2019 vs 2020
Adjusted EBITDA 2019 vs 2020 ChromaDex Corporation and Subsidiaries Reconciliation of Non-GAAP Financial Measures (In thousands) Year ended Year over Year Dec. 31.2019 Dec. 31, 2020 Change Net loss, as reported S (32147) $ (19,925) S122 Adjustments: Interest expense 847 1 (776) Depreciation 762 871
Slide 24: Q4 2020 Financial Highlights - Recap
Q4 2020 Financial Highlights - Recap + Total net sales of $15.4 million in Q4 2020 (+18% YoY, +9% versus Q3 2020) + Demonstrated continued progress building Tru Niagen® into a global brand + Tru Niagen® net sales of $12.3 million in Q4 2020 (+21% YoY) + Continued sequential growth in Tru Niagen® net
Slide 25: Contact Info
TRU NIAGEN Contact Info Brianna Gerber Vice President of FP&A and Investor Relations T: +1.949.419.0288 ext. 127 BriannaG@chromadex.com www.chromadex.com Where to buy TRU NIAGEN® www.truniagen.com www.amazon.com 25